There has been just one case of Mpox confirmed in Ireland so far this year.
The Health Service Executive said that communication with the key affected population - gay, bisexual and other men who have sex with men - and the roll-out of a vaccine programme contributed to the decline in cases.
There were 227 reported cases in 2022.
Monkeypox was renamed Mpox by the World Health Organization (WHO) in November in a bid to avoid stigmatisation.
Monkeypox received its name because the virus was originally identified in monkeys kept for research in Denmark in 1958, but the disease is found in a number of animals, and most frequently in rodents.
Medical Director of the HSE Sexual Health and Crisis Pregnancy Programme and consultant in genitourinary medicine at St James's Hospital Professor Fiona Lyons said that Ireland has "come a long way," but uncertainty remains.
Professor Lyons said: "Since the outbreak was declared first in May of last year, we've come a long way and really since the middle to end of August we've seen a significant decline in the number of cases being diagnosed in Ireland and this has been mapped out mostly across the rest of the world as well and this is very welcome."
She said that this trend has been seen before. Many previous outbreaks of Mpox declared outside of endemic parts of the world "have seen that eventually it does fizzle out and go away".
"There remain many uncertainties. We don't know what the future brings because we've never seen anything quite like what we've experienced since May of last year."
Adam Shanley is programme manager of MPOWER at HIV Ireland.
MPOWER works with members of the gay and bisexual community to design and implement activities to help reduce HIV and other sexually transmitted infections.
The WHO this week published a profile on how MPOWER responded to the different stages of the outbreak.
Mr Shanley is a member of the Mpox Crisis Management Team and described his role as a "community representative for the affected population".
He said: "I think we're in a very good position and it's testament to the work that we've put in in the last nine or so months.
"The UK, our closest neighbour, was an epicentre for the Mpox outbreak and yet we were able to maintain relatively low numbers in comparison."
But he warned that a "resurgence of the virus is not unimaginable".
"The outbreak is not over. There are still cases being identified in countries across Europe and particularly in South America, some in North America, but mostly South America.
"As we move into the summer period and travel takes off again, there is the potential for resurgence.
"Really what we're looking towards now is achieving and sustaining the elimination of Mpox and our key tool to sustaining elimination is really vaccinating those who are at a higher risk of acquiring Mpox in this outbreak., that's gay and bisexual men.
"A lot of our focus in the last quarter of last year was to ramp up access to Mpox vaccination.
"While there was really strong demand initially for uptake of the vaccine, it didn't reach the numbers that we had expected and so we're looking now at how we can encourage more people to access the vaccine that would be eligible for it."
On the issue of vaccine take-up, Professor of Experimental Immunology at Trinity College Dublin Kingston Mills said that reduced numbers of people presenting for vaccines could be explained by the fall off in public discussion on Mpox.
Professor Mills said: "There's very often a correlation between the amount of publicity in the media around a particular infectious disease and the uptake of the vaccine if there is one against it.
"That's clearly been seen with Covid-19, but also probably with Monkeypox, so when it's in the media all the time everybody is reminded of the risks and then they are aware of the benefit of the vaccine so they'll go out and get vaccinated."
